The presence of germline and somatic mutations in genes involved in homologous recombination (HR), including PALB2, was highly predictive of primary platinum (another group of crosslinking agents) sensitivity (p = 0.0002) and improved overall survival (p = 0.0006) in patients with ovarian, fallopian tube and peritoneal carcinoma. This evidence concerns the gene PALB2 and peritoneal carcinoma.